ServiceNow Inc vs Sanofi SA — how do they compare? ServiceNow Inc trades at $124.77 (market cap $131.86B), while Sanofi SA trades at $43.7 (market cap $104.30B). The key difference: ServiceNow Inc is the larger of the two by market cap, and Sanofi SA pays a 5.55% dividend while ServiceNow Inc pays none. Which is the better fit depends on your goals.
| NOW | SNY | |
|---|---|---|
Market Cap | $131.86B | $104.30B |
Sector | Technology | Health |
52-Week High | $192.23 | $52.34 |
52-Week Low | $83.00 | $41.33 |
Enterprise Value | $135.65B | $124.19B |
Dividend Yield | — | 5.55% |
Signals from Pluang's Aura AI — not financial advice
ServiceNow (NOW) trades at $127.44, up 2.05% today, with a bullish technical outlook supported by moving averages but overbought RSI signals. Revenue grew to $13.28B in 2025, with a net income margin of 11.34%, though high P/E of 79.71 indicates premium valuation. Recent news highlights AI-driven growth opportunities, including partnerships and conference presentations in June 2026.
The stock offers growth potential from AI adoption and strong cash flows, but faces risks from elevated valuations and competitive pressures. Analyst consensus is strongly bullish with an average price target of $138.26, though investors should monitor earnings consistency and macroeconomic headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →